Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis.
Musacchio L, Valsecchi AA, Salutari V, Valabrega G, Camarda F, Tuninetti V, Giannone G, Bartoletti M, Marchetti C, Pignata S, Fagotti A, Scambia G, Di Maio M, Lorusso D. Musacchio L, et al. Among authors: marchetti c. Cancer Treat Rev. 2022 Nov;110:102458. doi: 10.1016/j.ctrv.2022.102458. Epub 2022 Aug 24. Cancer Treat Rev. 2022. PMID: 36063572 Review.
Treatment of recurrent epithelial ovarian cancer.
Pisano C, Bruni GS, Facchini G, Marchetti C, Pignata S. Pisano C, et al. Among authors: marchetti c. Ther Clin Risk Manag. 2009 Aug;5(4):421-6. doi: 10.2147/tcrm.s4317. Epub 2009 Jun 22. Ther Clin Risk Manag. 2009. PMID: 19753136 Free PMC article.
Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.
Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignata S, Tomao F, Benedetti Panici P, Nuti M. Bellati F, et al. Among authors: marchetti c. Crit Rev Oncol Hematol. 2012 Jul;83(1):35-46. doi: 10.1016/j.critrevonc.2011.09.006. Epub 2011 Nov 4. Crit Rev Oncol Hematol. 2012. PMID: 22056314 Review.
Olaparib, PARP1 inhibitor in ovarian cancer.
Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti Panici P. Marchetti C, et al. Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. doi: 10.1517/13543784.2012.707189. Epub 2012 Jul 13. Expert Opin Investig Drugs. 2012. PMID: 22788971 Review.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Among authors: marchetti c. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients.
Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, Romito A, Piacenti I, Musio D, Muzii L, Tombolini V, Benedetti Panici P. Marchetti C, et al. Cancer Treat Rev. 2016 Jan;42:41-6. doi: 10.1016/j.ctrv.2015.10.011. Epub 2015 Nov 10. Cancer Treat Rev. 2016. PMID: 26559739 Review.
878 results